bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure 2. from A Positive Feedback Loop of lncRNA-PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion
Authors: Xu Mi-die , Wang Yiqin , Weng Weiwei , Wei Ping , Qi Peng , Zhang Qiongyan , Tan Cong , Ni Shu-juan , Dong Lei , Yang Yusi , Lin Wanrun , Xu Qinghua , Huang Dan , Huang Zhaohui , Ma Yuqing , Zhang Wei , Sheng Weiqi , Du Xiang
Published: April 2023

The effect of FOXM1-PVT1 loop on EZH2, c-Myc and NOP2 in GC AGS cells were transfected with the indicated plasmids or siRNA for 48 h. The western blot results showed the protein level of FOXM1, EZH2, c-Myc and NOP2 in each group.
SupplementarydataREV from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

supplemental Material and methods and supplementary figure legends
Fig.s3new from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

Figure S3 shows H&E on intrabone lesions and matrix deposition quantification
Supplemental Figures 3-4 from Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Authors: Kalbasi Anusha , Komar Chad , Tooker Graham M. , Liu Mingen , Lee Jae W. , Gladney Whitney L. , Ben-Josef Edgar , Beatty Gregory L.
Published: April 2023

Supplemental Figure 3: Ablative RT augments CCL2 in tumors; Supplemental Figure 4: PDAC cell lines induce migration of inflammatory monocytes
Fig.S4 from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

Figure S4 shows qPCR validation of data from Immune Panel card and in vitro analysis of chemokine expression upon trabectedin treatment
Fig.S1new from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

figure S1 shows in vitro and in vivo cell line characterization
Supplementary table 3 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary Table 3. ACSN functional modules enrichment by unique genes robustly correlated with survival to Olaparib in BC cell lines. Red - positive correlation, green - negative correlation, (P value <0.02).
Supplementary figure S2 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary figure S2. Correlation between sensitivity of tumor cells to AsiDNA and olaparib. Survival was moniored by trypan blue staining and manual counting (6 days after treatment). Survivals are expressed as % of living non treated cells. Correlation analysis between survival to AsiDNA and olaparib was performed using GraphPadPrism5 software and indicates a non significant correlation.
Supplementary Figures 1-11 from Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms
Authors: Lee JongBok , Minden Mark D. , Chen Weihsu C. , Streck Elena , Chen Branson , Kang Hyeonjeong , Arruda Andrea , Ly Dalam , Der Sandy D. , Kang Sohyeong , Achita Paulina , D'Souza Cheryl , Li Yueyang , Childs Richard W. , Dick John E. , Zhang Li
Published: April 2023

Figure S1. Characterization of ex vivo expanded healthy donor (HD) DNTs; Figure S2. Allogeneic DNTs induce dose- and time- dependent cytotoxicity against leukemic cells; Figure S3. Correlation between the susceptibility of AML patient blasts to DNT-mediated cytotoxicity and clinical features; Figure S4. Potency of anti-leukemic function mediated by allogeneic DNTs; Figure S5. Cytotoxic function of allogeneic DNTs on normal peripheral blood myeloid cells; Figure S6. NKp30, NKp44, and NKp46 are not involved in DNT-mediated killing of AML; Figure S7. Level of IFNγ production by DNTs corresponds with the level of cytotoxicity mediated by DNTs; Figure S8. DNAM-1 and NKG2D blocking abrogates IFNγ production by DNTs; Figure S9. IFNγ treatment does not affect the NKG2D and DNAM-1 ligand expression on normal PBMC; Figure S10. Cytotoxic activity of DNTs against leukemia cell lines derived from different types of leukemia and lymphoma; Figure S11. Effect of cryopreservation on the viability and anti-leukemic activity of ex vivo expanded DNTs.
Supplementary Figure Legend from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
Authors: Zook Phillip , Pathak Harsh B. , Belinsky Martin G. , Gersz Lawrence , Devarajan Karthik , Zhou Yan , Godwin Andrew K. , von Mehren Margaret , Rink Lori
Published: April 2023

Supplementary Figure Legend
Supplementary Figures 3, 4, & 5 from A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Authors: Sayyid Rashid K. , Evans Andrew , Hersey Karen , Maloni Ranjena , Hurtado-Coll Antonio , Kulkarni Girish , Finelli Antonio , Zlotta Alexandre R. , Hamilton Robert , Gleave Martin , Fleshner Neil E.
Published: April 2023

Supplementary Figure 3. Intratumoral dihydrotestosterone (DHT): Histogram representing intratumoral DHT from each patient in the degarelix arm. (ONLINE ONLY) Supplementary Figure 4. Intratumoral dihydrotestosterone (DHT): Histogram representing intratumoral DHT from each patient in the degarelix and bicalutamide arm. (ONLINE ONLY) Supplementary Figure 5. Intratumoral dihydrotestosterone (DHT): Histogram representing intratumoral DHT from each patient in the LHRH agonist and bicalutamide arm. (ONLINE ONLY)
Supplementary figures from miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma
Authors: Chang Rui-Min , Xiao Shuai , Lei Xiong , Yang Hao , Fang Feng , Yang Lian-Yue
Published: April 2023

Figure S1. Diagrammatic sketch of patients enrolled and groups designed. The detailed description was supplied in Method and Materials. Figure S2. In situ hybridization showed the miR-487a expression in HCC tissues. Figure S3. The infective efficiency of lentivirus in HCC cells. Figure S4. miR-487a promotes proliferation of HCC cells. Figure S5. miR-487a promotes proliferation and metastasis of MHCC97H and PLC/PRF/5. Figure S6. Protein and mRNA expression of SPRED2 and PIK3R1 in HCC tissues. Figure S7. miR-487a promotes proliferation via PIK3R1, but not SPRED2. Figure S8. miR-487a promotes proliferative or metastatic activity of HCC cells via PIK3R1 or SPRED2. Figure S9. miR-487a may promote proliferation or metastasis by regulating PIK3R1 mediated p-AKT or SPRED2 mediated p-ERK. Figure S10. Silencing of miR-487a suppresses HCC tumor growth and metastasis in vivo. Figure S11. The SPRED2, p-ERK, PIK3R1, p-AKT expression in serials sections of tumors collected from mice of HCCLM3Anti-miR-487a group and HCCLM3NC group. Figure S12. Schematic representation of the role and molecular mechanism of miR-487a in HCC. Figure S13. HCCLM3 cell labeled with luciferase is detectable by IVIS system. Figure S14. Morpholino-anti-miR-487a effectively suppresses the metastasis of HCC cells in HCC lung metastasis mouse model.
Supplementary Materials 1 and 2 from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Cell lines (Supplementary Material 1), Primer sequences and Antibodies (Supplementary Material 2).
Supplementary Figure S3 from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Depletion of CDA expression by short hairpin RNA in HeLa cells.
Supplementary Figure 1 from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

Optimization of the 10-gene signature screening protocol in FFPE samples and effect of long-term storage of FFPE samples on RNA quality
Supplementary from Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
Authors: Antonarakis Emmanuel S. , Kibel Adam S. , Yu Evan Y. , Karsh Lawrence I. , Elfiky Aymen , Shore Neal D. , Vogelzang Nicholas J. , Corman John M. , Millard Frederick E. , Maher Johnathan C. , Chang Nancy N. , DeVries Todd , Sheikh Nadeem A. , Drake Charles G.
Published: April 2023

Supplementary data - Table S1. Incidence of all adverse events occurring in {greater than or equal to}15% of patients as well as grade 3 to 5 adverse events* Figure S1. Study schematic. Figure S2. Time-to-PSA progression* from testosterone recovery to {greater than or equal to}175 ng/dL. Figure S3. Time-to-testosterone recovery. Figure S4. Time-to-next anti-cancer intervention in both arms. Figure S5. Comparison of humoral antigen spread at week 2 between STAND versus IMPACT and STAMP. Figure S6. Sipuleucel-T parameters: (A) TNC count, (B) APC count, and (C) APC activation in autologous peripheral blood mononuclear cells after ex vivo PA2024 activation. Figure S7. Comparison of APC activation (CD54+ upregulation) between STAND and IMPACT.
Figure S6 from Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Authors: Zhang Jia-Xing , Chen Zhen-Hua , Xu Yi , Chen Jie-Wei , Weng Hui-Wen , Yun Miao , Zheng Zou-San , Chen Cui , Wu Bing-Li , Li En-Min , Fu Jian-Hua , Ye Sheng , Xie Dan
Published: April 2023

The wound healing assay (A), and sphere formation assay (B) shows that LY294002 could abrogate the effect of PITX2 restoration on cell invasion ability and stem-like traits in miR-644a-overexpressing ESCC cells. **P<0.01, *P<0.05.
Figure legend for Supplemental Figure S1 from High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial
Authors: Nielsen Torsten O. , Jensen Maj-Brit , Burugu Samantha , Gao Dongxia , Jørgensen Charlotte L. Tykjaer , Balslev Eva , Ejlertsen Bent
Published: April 2023

Overall Survival analyses. A: Kaplan-Meier estimates of the DBCG77B TMA-IHC intrinsic subtype dataset, stratified by chemotherapy (CT) and Luminal A status, out to 25-yr follow-up. B: Forest plot, stratified by time since randomization due to non-proportionality of the hazard ratio for treatment effect across the full follow-up period.
Supplementary tables from Circular RNA ciRS-7—A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer
Authors: Weng Wenhao , Wei Qing , Toden Shusuke , Yoshida Kazuhiro , Nagasaka Takeshi , Fujiwara Toshiyoshi , Cai Sanjun , Qin Huanlong , Ma Yanlei , Goel Ajay
Published: April 2023

Supplementary tables
Supplementary figures from Circular RNA ciRS-7—A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer
Authors: Weng Wenhao , Wei Qing , Toden Shusuke , Yoshida Kazuhiro , Nagasaka Takeshi , Fujiwara Toshiyoshi , Cai Sanjun , Qin Huanlong , Ma Yanlei , Goel Ajay
Published: April 2023

Supplementary figures 1-5
Figure S6 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Authors: Yin Yuan , Yao Surui , Hu Yaling , Feng Yuyang , Li Min , Bian Zehua , Zhang Jiwei , Qin Yan , Qi Xiaowei , Zhou Leyuan , Fei Bojian , Zou Jian , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S6. miR-155-5p is critical for the chemoresistance of CRC through inhibiting IL-6 secretion in macrophages.
Figure S5 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Authors: Yin Yuan , Yao Surui , Hu Yaling , Feng Yuyang , Li Min , Bian Zehua , Zhang Jiwei , Qin Yan , Qi Xiaowei , Zhou Leyuan , Fei Bojian , Zou Jian , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S5. miR-204-5p reverses the macrophages-induced CRC chemoresistance.
Figure S4 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Authors: Yin Yuan , Yao Surui , Hu Yaling , Feng Yuyang , Li Min , Bian Zehua , Zhang Jiwei , Qin Yan , Qi Xiaowei , Zhou Leyuan , Fei Bojian , Zou Jian , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S4. CRC-conditioned macrophages induce CRC chemoresistance by secreting IL-6.
Figure S3 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Authors: Yin Yuan , Yao Surui , Hu Yaling , Feng Yuyang , Li Min , Bian Zehua , Zhang Jiwei , Qin Yan , Qi Xiaowei , Zhou Leyuan , Fei Bojian , Zou Jian , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S3. Macrophages modulate CRC chemoresistance through IL-6.
Supplementary Methods, Supplementary Tables, Supplementary Figure legends from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Authors: Depreeuw Jeroen , Stelloo Ellen , Osse Elisabeth M. , Creutzberg Carien L. , Nout Remi A. , Moisse Matthieu , Garcia-Dios Diego A. , Dewaele Michael , Willekens Karen , Marine Jean-Christophe , Matias-Guiu Xavier , Amant Frédéric , Lambrechts Diether , Bosse Tjalling
Published: April 2023

This file describes additional methodology, Supplementary Tables and Supplementary Figure legends.
Supplemental Table 1 from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Authors: Ogitani Yusuke , Aida Tetsuo , Hagihara Katsunobu , Yamaguchi Junko , Ishii Chiaki , Harada Naoya , Soma Masako , Okamoto Hiromi , Oitate Masataka , Arakawa Shingo , Hirai Takehiro , Atsumi Ryo , Nakada Takashi , Hayakawa Ichiro , Abe Yuki , Agatsuma Toshinori
Published: April 2023

Histopathological findings in the intestines, bone marrow and lung in the repeated dose study in monkeys
Supplemental Figures 1-8 from Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Authors: Lochmann Timothy L. , Floros Konstantinos V. , Naseri Mitra , Powell Krista M. , Cook Wade , March Ryan J. , Stein Giovanna T. , Greninger Patricia , Maves Yuki Kato , Saunders Laura R. , Dylla Scott J. , Costa Carlotta , Boikos Sosipatros A. , Leverson Joel D. , Souers Andrew J. , Krystal Geoffrey W. , Harada Hisashi , Benes Cyril H. , Faber Anthony C.
Published: April 2023

Supplemental Figure 1. Venetoclax sensitivity and BCL-2 mRNA correlation analysis; Supplemental Figure 2. Cell viability assays of border line venetoclax-sensitive and - resistant SCLC cell lines and combination of venetoclax with chemotherapy; Supplemental Figure 3. Correlation analysis of BCL-2 family members to venetoclax sensitivity in SCLC cell lines; Supplemental Figure 4. Comparison of BCL-2 family members to venetoclax sensitivity in SCLC cell lines; Supplemental Figure 5. BCL-2 mRNA expression is increased in SCLC compared to other cancer types; Supplemental Figure 6. Cell viability of venetoclax-sensitive and -resistant SCLC cell lines; Supplemental Figure 7. Weight profiles of xenograft and PDX models treated with venetoclax; Supplemental Figure 8. The PDX models from this study express high levels of BCL-2.
Supplementary Table 4. Serum levels of vitamin D. from Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial
Authors: Caballero-Velázquez Teresa , Montero Isabel , Sánchez-Guijo Fermín , Parody Rocío , Saldaña Raquel , Valcarcel David , López-Godino Oriana , Ferra i Coll Christelle , Cuesta Marian , Carrillo-Vico Antonio , Sánchez-Abarca Luis I. , López-Corral Lucía , Márquez-Malaver Francisco J. , Pérez-Simón José A.
Published: April 2023

Serum levels of vitamin D. Serum levels of vitamin D. The plasma levels of 25-hydroxi-VitD are summarized in this table
Figure S3 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Authors: Ramanathan Ramesh K. , Korn Ronald L. , Raghunand Natarajan , Sachdev Jasgit C. , Newbold Ronald G. , Jameson Gayle , Fetterly Gerald J. , Prey Joshua , Klinz Stephan G. , Kim Jaeyeon , Cain Jason , Hendriks Bart S. , Drummond Daryl C. , Bayever Eliel , Fitzgerald Jonathan B.
Published: April 2023

Correlation between FMX 72-hour signals and binding constant. (A) Mechanistic PK model for tumor deposition of FMX driven by permeability and binding parameters; example for lesion fits for low permeability/low signal retention is shown. (B) Correlation for tissue binding parameter B to FMX signal measured at 72 hours. The normalized FMX ratio between tumor and plasma values is shown to account for plasma FMX PK variability.
Figure S1 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Authors: Ramanathan Ramesh K. , Korn Ronald L. , Raghunand Natarajan , Sachdev Jasgit C. , Newbold Ronald G. , Jameson Gayle , Fetterly Gerald J. , Prey Joshua , Klinz Stephan G. , Kim Jaeyeon , Cain Jason , Hendriks Bart S. , Drummond Daryl C. , Bayever Eliel , Fitzgerald Jonathan B.
Published: April 2023

Sequence of study procedures.
Supplementary Figure Legends from Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage
Authors: Zhou Weihua , Xu Jie , Li Haomin , Xu Ming , Chen Zhijian J. , Wei Wenyi , Pan Zhenqiang , Sun Yi
Published: April 2023

Supplementary Figure Legends and Materials
Supplementary Figure 6 from Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms
Authors: Patel Dhaval , Thompson Matthew D. , Manna Soumen K. , Krausz Kristopher W. , Zhang Lisa , Nilubol Naris , Gonzalez Frank J. , Kebebew Electron
Published: April 2023

(A) Multivariate ROC curve analysis showing AUC with the combination of validated markers including creatine riboside and the four unidentified novel biomarkers. (B) Multivariate ROC curve analysis showing AUC with the combination creatine riboside and size of tumor.
Supplementary Figure Legends from CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study
Authors: Ng Chaan S. , Zhang Zheng , Lee Susanna I. , Marques Helga S. , Burgers Kyle , Su Feng , Bauza Joseph , Mannel Robert S. , Walker Joan L. , Huh Warner King , Rubin Stephen C. , DiSilvestro Paul , Martin Lainie P. , Chan John K. , Bookman Michael A. , Coleman Robert L. , Lee Ting-Yim
Published: April 2023

Legends for the supplementary figures
Supplementary Material from Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis
Authors: Pichler Martin , Stiegelbauer Verena , Vychytilova-Faltejskova Petra , Ivan Cristina , Ling Hui , Winter Elke , Zhang Xinna , Goblirsch Matthew , Wulf-Goldenberg Annika , Ohtsuka Masahisa , Haybaeck Johannes , Svoboda Marek , Okugawa Yoshinaga , Gerger Armin , Hoefler Gerald , Goel Ajay , Slaby Ondrej , Calin George Adrian
Published: April 2023

Contains the Methods and Material in all Details
Supplementary Figure Legends from Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis
Authors: Pichler Martin , Stiegelbauer Verena , Vychytilova-Faltejskova Petra , Ivan Cristina , Ling Hui , Winter Elke , Zhang Xinna , Goblirsch Matthew , Wulf-Goldenberg Annika , Ohtsuka Masahisa , Haybaeck Johannes , Svoboda Marek , Okugawa Yoshinaga , Gerger Armin , Hoefler Gerald , Goel Ajay , Slaby Ondrej , Calin George Adrian
Published: April 2023

Legends for the supplementary Figures
Supplemental Table 4 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Authors: Liu Joyce F. , Palakurthi Sangeetha , Zeng Qing , Zhou Shan , Ivanova Elena , Huang Wei , Zervantonakis Ioannis K. , Selfors Laura M. , Shen Yiping , Pritchard Colin C. , Zheng Mei , Adleff Vilmos , Papp Eniko , Piao Huiying , Novak Marian , Fotheringham Susan , Wulf Gerburg M. , English Jessie , Kirschmeier Paul T. , Velculescu Victor E. , Paweletz Cloud , Mills Gordon B. , Livingston David M. , Brugge Joan S. , Matulonis Ursula A. , Drapkin Ronny
Published: April 2023

Table S4: Somatic Sequence Alterations in parental tumor and xenograft DF101
Supplementary Figure S3 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Individual gene plots showing anti-correlated DNA methylation and expression. Genes selected for further validation are highlighted with a red asterisk.
Supplemental Figure 4 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 4. The therapeutic function of anti-CD20 is NK cell-independent.
Supplemental Figure 2 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 2. DT could deplete DCs efficiently in CD11c-DTR mice, without affecting macrophages so much.
Figure S1 from Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer
Authors: Liu Jin , Agopiantz Mikaël , Poupon Joël , Wu Zherui , Just Pierre-Alexandre , Borghese Bruno , Ségal-Bendirdjian Evelyne , Gauchotte Guillaume , Gompel Anne , Forgez Patricia
Published: April 2023

Figure S1 shows the NTSR1 expression in A2780 cells and the carboplatin response in A2780 wild type and A2780-R1 cells.
Supplementary Table S1, S2, Supplementary Figure S1 from FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Authors: O'Leary Maura C. , Lu Xiaobin , Huang Ying , Lin Xue , Mahmood Iftekhar , Przepiorka Donna , Gavin Denise , Lee Shiowjen , Liu Ke , George Bindu , Bryan Wilson , Theoret Marc R. , Pazdur Richard
Published: April 2023

Supplementary Table S1, S2, Supplementary Figure S1
Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Authors: Landa Iñigo , Pozdeyev Nikita , Korch Christopher , Marlow Laura A. , Smallridge Robert C. , Copland John A. , Henderson Ying C. , Lai Stephen Y. , Clayman Gary L. , Onoda Naoyoshi , Tan Aik Choon , Garcia-Rendueles Maria E.R. , Knauf Jeffrey A. , Haugen Bryan R. , Fagin James A. , Schweppe Rebecca E.
Published: April 2023

Supplementary Methods, Supplementary Figure and Table Legends
Supplementary Data from Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530
Authors: Locatelli Silvia L. , Careddu Giuseppa , Serio Simone , Consonni Francesca M. , Maeda Akihiro , Viswanadha Srikant , Vakkalanka Swaroop , Castagna Luca , Santoro Armando , Allavena Paola , Sica Antonio , Carlo-Stella Carmelo
Published: April 2023

Supplementary Fig. S1. Constitutive activation of the PI3K/Akt pathway in Hodgkin lymphoma patients and cell lines. Supplementary Fig. 2. Profiling of RP6530 target genes and related enriched pathways. Supplementary Fig. S3. Relevant KEGG pathway in GSEA preranked analysis of RP6530- modulated genes. Supplementary Fig. S4. Relevant PID pathway in GSEA preranked analysis of RP6530- modulated genes. Supplementary Fig. S5. RP6530 inhibits tumor glycolysis and HIF1ð�›, pathways. Supplementary Fig. S6. Validation of PKM2 inhibition in HL cell lines treated with RP6530. Supplementary Fig. S7. RP6530 induced cell death in M1 and M2 stimulated macrophages. Supplementary Fig. S8. PKM2-dependent macrophage class switch. Supplementary Fig. 9. RP6530 modulates TAMs polarization in HL xenografts. Supplementary Fig. S10. RP6530 induces tumor vasculature disruption.
Supplemental Figure 6 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Authors: Dovedi Simon J. , Cheadle Eleanor J. , Popple Amy L. , Poon Edmund , Morrow Michelle , Stewart Ross , Yusko Erik C. , Sanders Catherine M. , Vignali Marissa , Emerson Ryan O. , Robins Harlan S. , Wilkinson Robert W. , Honeychurch Jamie , Illidge Timothy M.
Published: April 2023

Treatment with FTY-720 has no direct effect on tumor growth and leads to deletion of non-LN resident and circulating T cells
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

Digital Sequencing-based ctDNA assay workflow. (a) cfDNA is extracted from stabilized peripheral whole blood, (b) labeled with oligonucleotide barcodes at high efficiency, and (c) up to 30ng is used for library preparation. (d) Sequencing libraries are enriched using hybrid capture and sequenced to an average depth of ~15,000x. (e) Individual unique input molecules are then bioinformatically reconstructed using barcode and sequence data to suppress analytical error modes. (f) Somatic variants are deconvoluted from germline and reported by clinical priority with both treatment and clinical trial annotations.
Supplementary Figure S1 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
Authors: Tokunaga Ryuma , Xiu Joanne , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Naseem Madiha , Lo Jae Ho , Arai Hiroyuki , Battaglin Francesca , Puccini Alberto , Berger Martin D. , Soni Shivani , Zhang Wu , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Baba Hideo , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Supplementary Figure S1. Histopathological subtypes of AA. A: adenocarcinoma, not otherwise specified (NOS: common colonic type). B: low-grade mucinous adenocarcinoma (MU) with pseudomyxoma peritonei (PMP). C: mucinous adenocarcinoma (MU). D: signet ring cell carcinoma (SR). All images are with hematoxylin and eosin stain.
Supplementary Table S3 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Putative BRCA1/2 reversion mutations identified in cfDNA of ovarian and breast cancer patients using targeted massively parallel sequencing and results of amplicon re-sequencing of putative BRCA2 reversion mutations and other somatic mutations in cfDNA and tumor tissue of metastatic breast cancers.
Sup Fig 2 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
Authors: Karnes R. Jeffrey , Sharma Vidit , Choeurng Voleak , Ashab Hussam Al-Deen , Erho Nicholas , Alshalalfa Mohammed , Trock Bruce , Ross Ashley , Yousefi Kasra , Tsai Harrison , Zhao Shuang G. , Tosoian Jeffrey J. , Haddad Zaid , Takhar Mandeep , Chang S. Laura , Spratt Daniel E. , Abdollah Firas , Jenkins Robert B. , Klein Eric A. , Nguyen Paul L. , Dicker Adam P. , Den Robert B. , Davicioni Elai , Feng Felix Y. , Lotan Tamara L. , Schaeffer Edward M.
Published: April 2023

Figure S2: Associations between PAM50 groups and ADT-RS signature
Figure S3 from BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models
Authors: Ganaie Arsheed A. , Beigh Firdous H. , Astone Matteo , Ferrari Marina G. , Maqbool Raihana , Umbreen Syed , Parray Aijaz S. , Siddique Hifzur R. , Hussain Tabish , Murugan Paari , Morrissey Colm , Koochekpour Shahriar , Deng Yibin , Konety Badrinath R. , Hoeppner Luke H. , Saleem Mohammad
Published: April 2023

Supplementary Figure 3. Average weight of animals receiving therapies.
Supplementary Figures S1-S10 from Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Authors: Orillion Ashley , Damayanti Nur P. , Shen Li , Adelaiye-Ogala Remi , Affronti Hayley , Elbanna May , Chintala Sreenivasulu , Ciesielski Michael , Fontana Luigi , Kao Chinghai , Elzey Bennett D. , Ratliff Timothy L. , Nelson David E. , Smiraglia Dominic , Abrams Scott I. , Pili Roberto
Published: April 2023

Additional data on the role of PR/MR on tumor microenvironment
Supplementary Figures from Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Authors: Yao Yung-mae M. , Donoho Gregory P. , Iversen Philip W. , Zhang Youyan , Van Horn Robert D. , Forest Amelie , Novosiadly Ruslan D. , Webster Yue Wang , Ebert Philip , Bray Steven , Ting Jason C. , Aggarwal Amit , Henry James R. , Tiu Ramon V. , Plowman Gregory D. , Peng Sheng-Bin
Published: April 2023

S1 and S2
Figure S3 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

CypA overexpression enhances GIC radio-resistance
Supplementary Figure S1: Effect of ipilimumab on immune subsets in human melanoma from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

A) The representative IHC micrographs for CD4+ and CD8+ cells from stage-matched untreated and Ipi-treated metastatic melanoma tumor sample at 10X and 20X magnifications (inset). Paired pre- and post-Ipi treated melanoma tumor samples from one responder (in red) and three non-responders (in black) analyzed by IHC for the presence of B) CD8+ cells and C) FOXP3+ cells.
Supplemental Tables from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

Supplemental Table 1A: Clinical and pathologic characteristics of postmenopausal patients with estrogen receptor-positive breast cancer treated with neoadjuvant aromatase inhibitors at MD Anderson under Z1031 protocol (n = 58) Supplemental Table 1B Biomarkers in the residual tumor Supplemental Table 2: Comparison of Clinical and pathologic characteristics of the MD Anderson cohort and the none-MD Anderson cohort on the Z1031 study. Supplemental Table 3: Ki67, preoperative endocrine prognostic index (PEPI) score, cytoplasmic low molecular weight cyclin E (LMW-E), and cytoplasmic phospho-CDK2 (pCDK2) in postmenopausal patients with estrogen receptor-positive breast cancer treated with neoadjuvant aromatase inhibitors at MD Anderson under Z1031 protocol (n = 58)
Supplemental Figure 6 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

Low molecular weight cyclin E (LMW-E) does not affect estrogen receptor gene transcription or aromatase activity.
Supplemental Table S1. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Patient Characteristics By Study
Supplemental Figure S2. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Sensitivity Analyses For the Median-Center and Proliferation Normalization of Microarray Data.
Supplemental Figure S1. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Individual proliferation genes versus proliferation gene expression signatures.
Supplementary Data from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Authors: Craddock Charles F. , Houlton Aimee E. , Quek Lynn Swun , Ferguson Paul , Gbandi Emma , Roberts Corran , Metzner Marlen , Garcia-Martin Natalia , Kennedy Alison , Hamblin Angela , Raghavan Manoj , Nagra Sandeep , Dudley Louise , Wheatley Keith , McMullin Mary Frances , Pillai Srinivas P. , Kelly Richard J. , Siddique Shamyla , Dennis Michael , Cavenagh Jamie D. , Vyas Paresh
Published: April 2023

Table S2. Details of Exons covered Table S4. Details of antibodies/ streptavidin used Table S5. Summary of longitudinal progenitor LSC quantitation by FACS Table S6. Overview of toxicities Figure S1. Progenitor LSC FACS gating strategy Figure S2. Kaplan-Meier plot for duration of response Figure S3. Forest plot of sub group analysis in overall response rate and overall survival.
Supplementary Table S2: Clinical trials in myeloma using MRD assessments from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Authors: Anderson Kenneth C. , Auclair Daniel , Kelloff Gary J. , Sigman Caroline C. , Avet-Loiseau Hervé , Farrell Ann T. , Gormley Nicole J. , Kumar Shaji K. , Landgren Ola , Munshi Nikhil C. , Cavo Michele , Davies Faith E. , Di Bacco Alessandra , Dickey Jennifer S. , Gutman Steven I. , Higley Howard R. , Hussein Mohamad A. , Jessup J. Milburn , Kirsch Ilan R. , Little Richard F. , Loberg Robert D. , Lohr Jens G. , Mukundan Lata , Omel James L. , Pugh Trevor J. , Reaman Gregory H. , Robbins Michael D. , Sasser A. Kate , Valente Nancy , Zamagni Elena
Published: April 2023

Active Clinical Trials in Myeloma Using Minimal Residual Disease Assessment as Exploratory or Secondary Endpoints
Supplementary Figure Legends from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Supplementary Fig 1. Discriminating gap size (DGS) criterion shows a gap in the distribution of the expression of MHC class II expression in the IPACTR cohort. Supplementary Fig 2. Immunohistochemical analysis of CD3, CD4, and CD8 expression.
Supplementary Fig. 2 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Immunohistochemical analysis of CD3, CD4, and CD8 expression. Row: a) adenoma; b) stage I carcinoma; and c) stage III carcinoma. Note that cells with short processes are dimly positive for CD4, consistent with macrophages; cells with long process are also dimly positive for CD4, consistent with dendritic cells (Magnification, 100x; inset, 400x).
Supplemental Figure 2 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Authors: Offin Michael , Rizvi Hira , Tenet Megan , Ni Andy , Sanchez-Vega Francisco , Li Bob T. , Drilon Alexander , Kris Mark G. , Rudin Charles M. , Schultz Nikolaus , Arcila Maria E. , Ladanyi Marc , Riely Gregory J. , Yu Helena , Hellmann Matthew D.
Published: April 2023

Univariate and multivariate analysis of TTD and OS by median TMB
Figure S4 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

BRCA1/2 mRNA
Figure S3 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

PTEn mRNA/Protien
Supplementary File 5 from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

Next-generation sequencing data by patient
Supplementary File 3 from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

Percent tumor cell content in H&E slides from patients where available
SupVideo1 from MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members
Authors: Yan Dan , Parker Rebecca E. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Vehicle
Supplementary Figure 3. from Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
Authors: Osswald Matthias , Blaes Jonas , Liao Yunxiang , Solecki Gergely , Gömmel Miriam , Berghoff Anna S. , Salphati Laurent , Wallin Jeffrey J. , Phillips Heidi S. , Wick Wolfgang , Winkler Frank
Published: April 2023

A, Metastasis sizes in the different treatment groups at start of treatment (p=0.596, ANOVA on Ranks). B, Quantifications of the mean grey values of the sodium fluorescein signal, normalized to background signal. Note that all metastases could clearly be attributed to be either permeable vs. non-permeable. There were no statistical significant differences between single metastases within the permeable (p=0.244, ANOVA) and the non-permeable (p=0.106, ANOVA) subgroups, when the different treatment groups were compared to each other. C, Quantification of growth rates per day after / before start of MCT control treatment (p=0.412, Mann-Whitney Rank Sum test).
Supplementary Figures and Tables from Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness
Authors: Park So-Yeon , Kim Ji-Young , Choi Jang-Hyun , Kim Jee-Heun , Lee Choong-Jae , Singh Pomila , Sarkar Shubhashish , Baek Jeong-Heum , Nam Jeong-Seok
Published: April 2023

Supplementary Figures and Tables
Supplementary Table S1 from FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Authors: Norsworthy Kelly J. , Luo Lola , Hsu Vicky , Gudi Ramadevi , Dorff Sarah E. , Przepiorka Donna , Deisseroth Albert , Shen Yuan-Li , Sheth Christopher M. , Charlab Rosane , Williams Gene M. , Goldberg Kirsten B. , Farrell Ann T. , Pazdur Richard
Published: April 2023

Preferred Terms included in grouped terms
Supplementary Materials and Methods from Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study
Authors: Visser Lindy L. , Elshof Lotte E. , Schaapveld Michael , van de Vijver Koen , Groen Emma J. , Almekinders Mathilde M. , Bierman Carolien , van Leeuwen Flora E. , Rutgers Emiel J. , Schmidt Marjanka K. , Lips Esther H. , Wesseling Jelle
Published: April 2023

Supplementary Materials and Methods
Figure S1 from Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer
Authors: Chera Bhishamjit S. , Kumar Sunil , Beaty Brian T. , Marron David , Jefferys Stuart , Green Rebecca , Goldman Emily C. , Amdur Robert , Sheets Nathan , Dagan Roi , Hayes D. Neil , Weiss Jared , Grilley-Olson Juneko E. , Zanation Adam , Hackman Trevor , Blumberg Jeffrey M. , Patel Samip , Weissler Mark , Tan Xianming M. , Parker Joel S. , Mendenhall William , Gupta Gaorav P.
Published: April 2023

Specificity, sensitivity and linearity of HPV16 dPCR assay
Figure S4 from Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Authors: L'Italien Lawrence , Orozco Olivia , Abrams Tinya , Cantagallo Lisa , Connor Anu , Desai Jayesh , Ebersbach Hilmar , Gelderblom Hans , Hoffmaster Keith , Lees Emma , Maacke Heiko , Schleyer Siew , Skegro Darko , Lee-Hoeflich Si Tuen
Published: April 2023

Confirmatory FACs binding of LMJ729 engineered Fc mutants
Figure S2 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Supplementary Figure 2. Trientine reduces anchorage-independent growth of BCPAP cells.
Supplementary Figure 2 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 2
Supplementary Movie (high delta) from A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
Authors: Koay Eugene J. , Lee Yeonju , Cristini Vittorio , Lowengrub John S. , Kang Ya'an , Lucas F. Anthony San , Hobbs Brian P. , Ye Rong , Elganainy Dalia , Almahariq Muayad , Amer Ahmed M. , Chatterjee Deyali , Yan Huaming , Park Peter C. , Rios Perez Mayrim V. , Li Dali , Garg Naveen , Reiss Kim A. , Yu Shun , Chauhan Anil , Zaid Mohamed , Nikzad Newsha , Wolff Robert A. , Javle Milind , Varadhachary Gauri R. , Shroff Rachna T. , Das Prajnan , Lee Jeffrey E. , Ferrari Mauro , Maitra Anirban , Taniguchi Cullen M. , Kim Michael P. , Crane Christopher H. , Katz Matthew H. , Wang Huamin , Bhosale Priya , Tamm Eric P. , Fleming Jason B.
Published: April 2023

Mathematical model simulation of high delta tumor growth (lambda = 1.5)
Legend to supplementary data from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
Authors: Mésange Paul , Bouygues Anaïs , Ferrand Nathalie , Sabbah Michèle , Escargueil Alexandre E. , Savina Ariel , Chibaudel Benoist , Tournigand Christophe , André Thierry , de Gramont Aimery , Larsen Annette K.
Published: April 2023

Legend to supplementary data